InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended September 30, 2014.
Mark Perrin, InVivo’s CEO, said, “We made substantial progress on all fronts during the third quarter and have continued to build upon that momentum in the weeks since. In that timeframe, we enrolled our first subject in our first-in-human pilot trial, expanded the number of potential clinical sites, broadened subject eligibility criteria, increased our communications outreach through scientific, medical, and investor conferences, and significantly strengthened our intellectual property portfolio.
Help employers find you! Check out all the jobs and post your resume.
Mark Perrin, InVivo’s CEO, said, “We made substantial progress on all fronts during the third quarter and have continued to build upon that momentum in the weeks since. In that timeframe, we enrolled our first subject in our first-in-human pilot trial, expanded the number of potential clinical sites, broadened subject eligibility criteria, increased our communications outreach through scientific, medical, and investor conferences, and significantly strengthened our intellectual property portfolio.
Help employers find you! Check out all the jobs and post your resume.
